AQUILON PHARMA PURCHASES PRECISEINHALE FOR INNOVATIVE ASTHMA AND COPD RESEARCH
Aquilon Pharma, based in Belgium, has purchased ISAB's high-precision R&D system PreciseInhale®, plus its Nose-Only and Intratracheal Exposure Modules, to help drive forward their innovative portfolio of new formulations to improve the efficacy of inhaled drugs for asthma and COPD (Chronic Pulmonary Obstructive disorder).
VISITING IN VITRO EXPERT PRAISES ISAB'S DISSOLVIT FOR 'ADVANCED AUTOMATION, USABILITY AND FLEXIBILITY'
Graz University's Snezana Radivojev completed a month's onsite contract research at ISAB's labs in Stockholm working with the advanced in vitro solution tool DissolvIt®.Radivojev has spent four years researching a wide range of simulated lung models - so how did DissolvIt® measure up?
NEW CHIEF COMMERCIAL OFFICER ONBOARD TO DRIVE GLOBAL SALES
Paolo Raffaelli has begun work as ISAB's Chief Commercial Officer (CCO). With over 20 years' executive experience in the life science and medical device industry, Mr Raffaelli is responsible for driving ISAB sales in Europe, the US and other international markets. 'I am very excited about the positive impact Inhalation Sciences can make for our customers' drug development process, de-risking their clinical trials already in the pre-clinical phase. PreciseInhale clearly offers the possibility to get pre-clinical research right the first time'.
ISAB SELECTS GLOBAL BRANDING AGENCY 'UP' FOR NEW DIGITAL MARKETING STRATEGY AND CAMPAIGN
ISAB has appointed global branding agency UP THERE, EVERYWHERE (UP) for a new digital marketing strategy that will include lead generation process, SEO (Search engine Optimisation) and highlighting of ISAB's Unique Selling Points. In ISAB's strategic plan for 2021 the company has prioritized increasing its digital brand and marketing capabilities in its drive to grow sales and leadership within its field.
ISAB APPOINTS NEW QUALITY AND REGULATORY AFFAIRS MANAGER
Helen Bäckroos is ISAB's new Quality and Regulatory Affairs Manager, a crucial role for ISAB's plan to expand PreciseInhale's use from pre-clinical to clinical research in 2021.
PRECISEINHALE RECEIVES EXTENDED INTERNATIONAL REGISTERED TRADEMARK
Inhalation Sciences' flagship high-precision aerosol generator for preclinical respiratory research, has received an extended international Registered Trademark from the International Bureau of the World Intellectual Property Organization (WIPO). ISAB CEO Manoush Masarrat: 'This will play an important role in protection of our trademark and driving the growth of PreciseInhale[®] in many strategic global markets.'